IRSF Field Report 2: '401 Drives Progressive Hand & Gross Motor Skill Gains

Research evidence excerpt

IRSF Field Report 2: '401 Drives Progressive Hand & Gross Motor Skill Gains

Biotechnology

Neurogene

TD SECURITIES (USA) LLC QUICK TAKE: CONFERENCE TAKEAWAY

June 30, 2026

Price: $32.28 (06/29/2026) IRSF Field Report 2: '401 Drives Progressive

Price Target: NA Hand & Gross Motor Skill Gains

BUY (1)

Ritu Baral THE TD COWEN INSIGHT

646 562 1379

NGNE presented add'l sub analyses from the updated IRSF Ph1/2 '401 dataset highlighting

ritu.baral@tdsecurities.com

gains in hand & gross motor function. '401 led to clinically meaningful improvements in

Athena Chin RSHFS-assessed hand function, w/ acquisition of advanced skills appearing dependent on

646 562 1468 baseline motor ability. RSGMS (gross-motor) data also showed hierarchical, developmentally

athena.chin@tdsecurities.com

progressive gains linked to baseline function.

Key Data

Symbol NASDAQ: NGNE Today at IRSF 2026 (June 29–July 1; Prior Lake, MN), NGNE presented additional subanalyses

Market Cap $510.1MM from the updated 12+ month Ph1/2 NGN-401 dataset. Presentations focused on changes

in hand function and gross motor function following '401 treatment, as well as caregiverClick here for the full company update from

perspectives on developmental milestone gains observed to date. We highlight the keyour latest quarterly report.

findings below.

NGN-401 Showed Clinically Meaningful Improvements In Hand Function, With Emerging

Evidence Of Progressive Acquisition Of More Complex Manual Skills

In the Ph1/2 '401 Rett study, hand function was assessed using both i) developmental

milestones included in the registrational Phase 3 EMBOLDEN trial and ii) the Rett Syndrome

Hand Function Scale (RSHFS), a clinically validated tool that measures hand function in 8

levels of increasing sequential complexity.